@misc{oai:repo.qst.go.jp:00085146,
 author = {長谷川, 純崇 and Sumitaka, Hasegawa},
 month = {Mar},
 note = {Uterine serous carcinoma (USC) is a rare but aggressive type 2 endometrial carcinoma with high recurrence rate and dismal prognosis. HER2 is a potential therapeutic target because 35-44% of USCs have HER2 overexpression or gene amplification. However, the efficacy of the anti-HER2 antibody, trastuzumab, is still limited. Astatine-211 (At-211), an alpha-ray emitting radionuclide, can deliver high doses to tumors while maintaining low doses to normal tissues due to its high linear energy transfer and short range. In this study, we investigated the pharmacological effects of At-211-armed trastuzumab (211At-Trastuzumab) in human USC cell lines. 211At-Trastuzumab bound to HER2-poditive USC cells in a cell number-dependent manner. These bindings were HER2-specific because an addition of non-labeled trastuzumab blocked the cell binding. 211At-Trastuzumab showed a significant cytotoxicity in HER2-poditive USC cells. 211At-Trastuzumab is a potential radiopharmaceutical for USC treatment., 第95回日本薬理学会年会},
 title = {Anti-tumor effects of alpha-ray emitting antibodies for uterine serous carcinoma},
 year = {2022}
}